Bristol-Myers Squibb's Opdivo couldn't topple Nexavar in HCC — but will better safety profile win over physicians?
BARCELONA — Bristol-Myers Squibb’s Opdivo couldn’t quite beat Nexavar, the standard of care in hepatocellular carcinoma, in its Phase III head-to-head. But investigators are still hoping that it can play a role in the frontline setting of this disease.
Thomas Yau of the University of Hong Kong, who led the Checkmate-459 study, hit hard on Opdivo’s “clinically meaningful” advantages over the entrenched therapy, particularly in terms of side effects and quality of life.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.